UNSPSC 51272115: Tetracaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C15H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5NF5D4OPCI, chemically known as p-(butylamino)benzoic acid, 2-(dimethylamino)ethyl ester, hydrochloride but more generally known as amethocaine hydrochloride, which bears US NIH Compound Identifier 8695. European Medicines Agency schedules Amethocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04754MIG.

Most nations, for tariff and trade purposes, schedule tetracaine hydrochloride under HS 29224995. As of Q4 2014, TETRACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tetracaine hydrochloride bears US NLM identifiers UMLS ID C0304456 and NCI Concept Code C75104. SMILES: CCCCNC1CCC(CC1)C(=O)OCCN(C)C.CL.

UNSPSC 51272115 Tetracaine hydrochloride is a Commodity code that designates a specific local anesthetic pharmaceutical agent, but recent state and local procurement activity tagged under this code does not reflect direct procurement of tetracaine itself. Instead, the opportunities posted against this code show state and local governments acquiring broader pharmaceutical and drug-management products—naloxone and drug deactivation systems through Seminole County, Florida; direct-to-manufacturer prescription fulfillment capability through Texas Health and Human Services Commission; and generic multi-source pharmaceuticals and OTC products through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). The mismatch between the code's nominal scope and actual solicitation content suggests that state and local procurement systems may be applying this code as a catch-all for pharmaceutical procurement rather than reserving it for tetracaine hydrochloride specifically. Issuing bodies soliciting under the code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. No recent opportunities targeting tetracaine hydrochloride as a line item have appeared.

Activity is geographically dispersed across Florida, Texas, and Minnesota with participation from cooperative purchasing members in additional states. The most recent opportunity—Seminole County, Florida's IFB 60459723LAS posted June 30, 2026, with response due July 26, 2026—seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota MMCAP issued RFP S1070000015802 in January 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract terms effective July 1, 2026, and performance penalties for late reporting or compliance failures.